Biodesix Inc. Achieves FDA Approval for Oncomine Dx Express Test, Expanding NGS Diagnostics Capabilities
Reuters
Aug 19
Biodesix Inc. Achieves FDA Approval for Oncomine Dx Express Test, Expanding NGS Diagnostics Capabilities
Biodesix Inc., a leader in personalized diagnostics, announced that it played a crucial role in the validation of Thermo Fisher's Oncomine Dx Express Test, leading to the FDA approval of the Genexus Dx Integrated Sequencer. As part of this achievement, Biodesix has been recognized as a Thermo Fisher Scientific Center of Excellence $(COE)$ for NGS Diagnostics. This recognition is part of Thermo Fisher's initiative to advance NGS-based diagnostics. The collaboration highlights Biodesix's commitment to enhancing molecular diagnostic and NGS testing capabilities, particularly in the field of oncology, and positions the company as a key player in transforming cancer diagnosis and care. There is no mention of a grant or funding obtained by multiple organizations in the provided context.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9514473-en) on August 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.